<DOC>
	<DOCNO>NCT02950428</DOCNO>
	<brief_summary>The purpose investigation collect data pertain safety performance ACURATE neo ( TM ) Aortic Bioprosthesis implant ACURATE neo ( TM ) TA Transapical Delivery System . This device intend treatment subject severe aortic stenosis ( AS ) high risk conventional aortic valve replacement ( AVR ) surgery . The ACURATE neo ( TM ) Aortic Bioprosthesis intend use via minimally-invasive transapical implantation well-defined population .</brief_summary>
	<brief_title>ACURATE Neo™ TA Delivery System Patient With Severe Aortic Stenosis</brief_title>
	<detailed_description>This single arm , prospective , multicenter non randomise open trial treatment patient severe aortic stenosis conventional aortic valve replacement ( AVR ) via open heart surgery consider high risk . All patient follow 5 year intervention . The primary objective evaluate safety performance study device patient present severe aortic stenosis consider high risk surgery Secondary objective evaluate adverse event study device performance .</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . Subject must least 18 year old 2 . Severe aortic stenosis define : Mean aortic gradient &gt; 40 mmHg Peak jet velocity &gt; 4.0 m/s Aortic valve area &lt; 0.8 cm2 3 . High risk patient determine multidisciplinary heart team consensus ( cardiologist cardiac surgeon ) patient surgical candidate conventional AVR due risk factor STS Score ( 8 % high ) comorbid condition unrelated aortic stenosis severe chronic obstructive pulmonary disease ( COPD ) , chest deformity irradiate mediastinum 4 . NYHA Functional Class &gt; II 5 . Multidisciplinary heart team ( cardiologist cardiac surgeon ) consensus transapical approach suitable access route TAVI due presence follow anatomic condition : porcelain aorta severely calcify highly tortuous peripheral vasculature appropriate transfemoral transcatheter aortic valve implantation vessel small retrograde approach anatomical condition make transapical approach suitable 6 . Aortic annulus diameter ≥ 21mm ≤ 27mm CT TEE 7 . Patient willing participate study provide sign informed consent 1 . Congenital unicuspid bicuspid aortic valve noncalcified 2 . Extreme eccentricity calcification 3 . Severe mitral regurgitation ( &gt; Grade 3 ) 4 . Preexisting prosthetic heart valve position / prosthetic ring 5 . LV apex accessible via transapical access due severe chest deformity 6 . Previous surgery LV use patch , Dor procedure 7 . Presence apical LV thrombus 8 . Calcified pericardium 9 . Septal hypertrophy unacceptable transapical procedure 10 . Transesophageal echocardiogram ( TEE ) contraindicate 11 . ECHO evidence intracardiac mass , thrombus , vegetation 12 . LVEF &lt; 20 % ECHO 13 . Need emergency intervention reason within 30 Days schedule procedure 14 . Any percutaneous intervention , except balloon valvuloplasty ( BAV ) within 1 month prior implant procedure 15 . Untreated clinically significant coronary artery disease require revascularization within 30 day study procedure 16 . Acute myocardial infarction within 1 month prior implant procedure 17 . Previous TIA stroke within 6 month prior implant procedure 18 . Active gastrointestinal ( GI ) bleed within 3 month prior implant procedure 19 . Scheduled surgical percutaneous procedure perform prior 30 day visit 20 . History bleed diathesis , coagulopathy , refusal blood transfusion severe anemia ( Hb &lt; 8 g/dL ) 21 . Systolic pressure &lt; 80mmHg , cardiogenic shock , need inotropic support IABP 22 . Primary hypertrophic obstructive cardiomyopathy ( HOCM ) 23 . Active infection endocarditis 24 . Hepatic failure ( &gt; Child B ) 25 . Chronic renal dysfunction serum creatinine &gt; 3.0 mg/dL renal dialysis 26 . Neurological disease severely affect ambulation , daily functioning , dementia 27 . Life expectancy &lt; 12 month due noncardiac comorbid condition 28 . Intolerance aspirin , clopidogrel , contrast medium , porcine tissue allergy nickel 29 . Pregnant breastfeed woman 30 . For severe illness patient ( e.g . active carcinoma ) , investigator shall decide individual basis whether patient include study 31 . Currently participate investigational drug another device study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>TAVI</keyword>
	<keyword>Aortic Stenosis</keyword>
	<keyword>transcatether Aortic Valve Implantation</keyword>
</DOC>